ArticlePsychiatry investigation2025
The Metabolic Signature of Autism Spectrum Disorders Using Dried Blood Spots at Birth.
Article in Psychiatry investigation, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
objectiveThis study aims to evaluate the metabolic impact of the autism spectrum disorder (ASD) at birth, while such insight may lead to increased understanding of the etiology.
methodsWe performed tandem mass spectrometry (TMS) in a large sample of dried blood spots (DBS) derived at birth from 106 autistic patients and 401 controls, to identify a metabolic signature for ASD. We also examined trait-specific metabolomic patterns within ASDs, focusing on the age, sex, and the comorbidities including the language delay (LD) and global developmental delays.
resultsThe results showed that there were no significant differences in metabolism data between ASD patients and controls. The forest plot analysis revealed distinct associations between genetic metabolic substances and autism in male and female populations. Among males, the variable C0 demonstrated a statistically significant association (odds ratio [OR]=1.05, 95% confidence interval [CI]: 1.006-1.096, p=0.024). For females, a significant association was observed with C3 (OR=2.541, 95% CI: 1.089-6.140, p=0.032). Based on their chronological ages of the first diagnosis, autistic individuals were divided in two groups: younger (n=59) or older than 3 years (n=47). The metabolism of succinic acid is increased (p<0.05), as well as carnitines C5:1.
conclusionMost analytes included in the TMS screen had no significant differences between the autism group and the control group at birth; however, sex, the age of first diagnose for ASD, and comorbidities may be the important factors affecting metabolic characteristics, as well as the genetic metabolic changes arise after birth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.